Regado Biosciences intends to price initial public offering of stock

Funds used for the Regulate-PCI trial, working capital and operations

By Devika Patel

Knoxville, Tenn., April 29 - Regado Biosciences, Inc. will price an initial public offering of common stock with a greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq under the symbol "RGDO."

Cowen and Co., BMO Capital Markets, Canaccord Genuity, Needham & Co. and Wedbush PacGrow Life Sciences are assisting.

Proceeds will be used for phase 3 Regulate-PCI trial, for working capital and to support operations.

The biopharmaceutical company is based in Basking Ridge, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.